Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Johnson & Johnson (JNJ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Johnson & Johnson (JNJ) - free report >>
Image: Bigstock
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
Eli Lilly & Company (LLY - Free Report) announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data for psoriasis involving the genital area, which impacts roughly 63% of psoriasis patients over the course of their disease.
Taltz is already marketed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy as well as for active psoriatic arthritis. Taltz works by specifically targeting IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.
The drug recorded sales of $146.5 million in the first quarter of 2018. The label expansion will expand the eligible patient population of the drug, which should drive sales going forward.
The approval for genital psoriasis was based on data from a study evaluating patients with moderate-to-severe psoriasis involving the genital area. In the study, Taltz demonstrated a significant improvement compared to placebo at 12 weeks in the severity of psoriasis affecting the genital area, overall psoriasis, genital itch and the impact of genital psoriasis on sexual activity in such patients.
Though many other drugs like Novartis’ (NVS - Free Report) Cosentyx, J&J’s (JNJ - Free Report) Tremfya and AbbVie’s (ABBV - Free Report) Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasis
Taltz is also being studied in a late-stage study for axial spondyloarthritis.
Year to date, Lilly’s shares have declined 2.6% compared with the industry’s decline of 3.8%.
Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>